L-Acetylcarnitine
|
Basic information |
| Metabolite name | L-Acetylcarnitine |
 | HMDB0000201 |
 |
C02571 |
 |
7045767 |
| Synonyms | Acetylcarnitine (C2); |
| No. of studies | 33 |
|
Basic information |
| Metabolite name | L-Acetylcarnitine |
| HMDB0000201 |
|
C02571 |
|
7045767 |
| Synonyms | Acetylcarnitine (C2); |
| No. of studies | 33 |
|
Relationship between L-Acetylcarnitine and depression (count: 33) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1041 | Type2 | pilocarpine + mitochondrial transplantation group vs. pilocarpine group | Hippocampus | C57BL/6J mouse | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M1077 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Up |
| Study M1099 | Type2 | chronic social isolation + fluoxetine group vs. chronic social isolation group | Prefrontal cortex | Wistar rat | Up |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M494 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Down |
| Study M587 | Type2 | MDD group, after 8-week SSRI treatment vs. before treatment | Plasma | Human | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, validation cohort | Plasma | Human | Down |
| Study M649 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Down |
| Study M749 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M818 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M818 | Type2 | MDD group, after 3-month antidepressant treatment vs. baseline | Plasma | Human | Up |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Up |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M847 | Type2 | CUMS + Bupleuri Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M856 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M856 | Type2 | effective group, post-treatment vs. baseline | Serum | Human | Up |
| Study M881 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M984 | Type1 | MDD group vs. control group | Serum | Human | Down |